
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. is strategically positioned within a lucrative market, as evidenced by the substantial $56 billion revenue generated by mRNA COVID-19 vaccines in 2022, indicating a strong demand for innovative antiviral solutions. The company’s development of VYD2311, which has received FDA support for its Phase 3 program, presents a significant opportunity to capture a larger target market and demonstrate the potential superiority of monoclonal antibodies over existing mRNA vaccines. Additionally, the incorporation of half-life extension technology in VYD2311, coupled with favorable biophysical characteristics, establishes a pathway for Invivyd to achieve best-in-class status and tap into a projected global market valued at $3-4 billion by 2030.
Bears say
Invivyd Inc. faces considerable challenges due to the misleading results from its in silico modeling, which revealed a 200-fold decrease in the efficacy of its antibody candidates against the omicron variant during the STAMP trial. Additionally, the effectiveness of mRNA vaccines, relevant to Invivyd's market, is declining, particularly among vulnerable populations such as the elderly and immunocompromised, further shrinking the commercially viable opportunity for the company’s products. Compounded by diminishing COVID-19 vaccination rates and growing vaccine hesitancy, the overall market opportunity for Invivyd's antibody-based solutions appears significantly reduced, impacting the company's financial outlook.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares